Pharmacogenetics for individualized cancer chemotherapy.
about
Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effectGenotyping panel for assessing response to cancer chemotherapy.Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing ProjectsA whole-genome SNP association study of NCI60 cell line panel indicates a role of Ca2+ signaling in selenium resistanceRecent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesBioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.Racial disparity in metabolic regulation of cancer.Pharmacogenetics and the concept of individualized medicine.Pharmacogenetics and pharmacogenomics of anticancer agents.The association of transporter genes polymorphisms and lung cancer chemotherapy responseConstruction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic methodIdentification of novel germline polymorphisms governing capecitabine sensitivity.Pharmacogenetics/genomics and personalized medicine.The emerging importance of DNA mapping and other comprehensive screening techniques, as tools to identify new drug targets and as a means of (cancer) therapy personalisation.Emerging drugs to replace current leaders in first-line therapy for breast cancer.Diagnosis and therapy of oral squamous cell carcinoma.Identifying genetic variants that contribute to chemotherapy-induced cytotoxicityPhytochemical regulation of UDP-glucuronosyltransferases: implications for cancer prevention.Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy.Part 1: background, methodology, and clinical adoption of pharmacogenetics.VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update.Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals.Pharmacogenetics of cancer therapy: breakthroughs from beyond?Pharmacogenomics of Scopoletin in Tumor Cells.Integration of phytochemicals and phytotherapy into cancer precision medicine.The pharmacoepigenetics of drug metabolism and transport in breast cancer: review of the literature and in silico analysis.Whole-genome approach implicates CD44 in cellular resistance to carboplatin.Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis.A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies.Polymorphism in glutathione S-transferases: susceptibility and treatment outcome for head and neck cancer.Aloe-emodin as drug candidate for cancer therapy.Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicityAssociation ofHMGB1andHMGB2genetic polymorphisms with lung cancer chemotherapy responseA comprehensive study of polymorphisms inABCB1, ABCC2andABCG2and lung cancer chemotherapy response and prognosis
P2860
Q28542007-C81FC8B2-90C0-411F-A7AF-AA223EF0FEC5Q33343095-D56966A9-F3E8-484F-B3F2-FB6D1C756E59Q33530851-947C0846-E4FD-420F-A629-65E1056C9B22Q33689387-09D373FE-7D42-45DF-AB1B-B16531410629Q33730375-41E50B5D-D002-4FE5-9C9D-EFB45A168C1DQ33818738-B6A55B23-D0D3-4D23-8DE1-609AA1E9FB34Q33906704-EB680065-1188-41DF-AF7E-66BE18352409Q34562770-42199897-5287-45AF-A446-BFA4F117A908Q35030489-A041303B-B38B-41F8-8CF2-2AF671E65D7DQ35124361-25D69F0C-F457-46E2-B5D7-3D0B93D38FE7Q35811012-78148371-3137-4BCA-898F-4EE9BD988B35Q36147462-C4F8DD00-E67C-4D00-86AA-996D7508284EQ36294685-A3951A01-CC02-4735-9FA1-6401853D9FA8Q36425978-2B44645B-C71A-43B6-A05E-31A682626EBDQ36580598-D824986E-D1A6-4A87-8250-EB79490FB0CEQ36752033-14538F84-F0D1-4651-91E2-3CD9EF40240EQ36966019-4BA375A5-45D1-4AD3-8E92-3446BEB78B76Q37000698-B2289E53-A178-46BE-837A-B20213683128Q37031517-A3D60355-A4C8-4CA5-856F-89AE67BD8666Q37414536-D8EB12A6-3283-4AB7-8FA2-3CC3270E8313Q37883726-14176DD9-F5C5-44A6-9177-BD76054ED576Q38148602-A61C193D-324D-4529-B3DA-655F1992D1ACQ38269745-78E7785A-C00E-4C1F-BE69-5CFFAFAB5A25Q38776883-60EA7E81-CEF1-4087-BF1B-D1FD3C9601A0Q38777193-1B3EAAB8-E4E8-4167-86C9-A463D745087DQ38780465-B3253EBD-DCB4-4EA2-B42B-7E14AF7316EDQ38937221-D282EE2C-73D9-4243-ADB0-3527D227899EQ39891877-6F3EB3CE-7BFC-4941-A71D-EDC977F7B080Q40008844-832D0048-3623-44EB-A1DE-7B199405FFACQ43973148-E6AC93E9-1F08-418C-9E74-525B0EDF98C7Q51852328-57A2BA8A-A1E3-4D30-AE13-518A7C9F6BA7Q52715777-A5725CB6-780D-4F7E-887E-15CD9E32FA0FQ57500197-EE2EBB09-A069-4A9E-8404-FBBAD15C97B0Q57500224-0ECA446F-710A-4900-9F35-DF28665BE95BQ57610444-34151B51-68C4-419D-9ABD-73029E20900A
P2860
Pharmacogenetics for individualized cancer chemotherapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pharmacogenetics for individualized cancer chemotherapy.
@ast
Pharmacogenetics for individualized cancer chemotherapy.
@en
type
label
Pharmacogenetics for individualized cancer chemotherapy.
@ast
Pharmacogenetics for individualized cancer chemotherapy.
@en
prefLabel
Pharmacogenetics for individualized cancer chemotherapy.
@ast
Pharmacogenetics for individualized cancer chemotherapy.
@en
P1476
Pharmacogenetics for individualized cancer chemotherapy
@en
P2093
Manfred Volm
P304
P356
10.1016/J.PHARMTHERA.2005.02.005
P577
2005-08-01T00:00:00Z